Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which nebulized solution best clears mucus in pneumonia? new trial aims to find out

NCT ID NCT07586345

Symptom relief Sponsor: Chen, Yao-Hsiang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests four different nebulized solutions (various salt concentrations and distilled water) to see which works best for clearing mucus from the airways of pneumonia patients. Eighty adults with pneumonia who need help coughing up phlegm will receive the treatment four times daily for seven days. Researchers will measure hospital stay length, blood gas levels, and sputum characteristics to find the most effective option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nebulized saline solutions (3% hypertonic, 0.9% normal, 0.45% hypotonic, and distilled water)
What this could lead to
If successful, this could provide clear guidance on which nebulized solution best helps pneumonia patients clear mucus, potentially shortening hospital stays.
What could go wrong
This is a small, early-stage study (80 people) comparing different concentrations of a common therapy, so results may not be definitive or widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed with pneumonia, defined by ICD-10 codes, including: J18: Pneumonia, unspecified organism J180: Bronchopneumonia, unspecified organism J181: Lobar pneumonia, unspecified organism J182: Hypostatic pneumonia, unspecified organism J188: Other pneumonia, unspecified organism J189: Pneumonia, unspecified organism 2. Aged 18-100 years 3. Clinical respiratory score \> 3 4. Patients unable to expectorate sputum spontaneously and requiring assisted suctioning Exclusion Criteria: 1. Diagnosis of influenza-associated pneumonia, defined by ICD-10 codes, including: J09X1: Influenza due to identified novel influenza A virus with pneumonia J1001: Influenza due to other identified influenza virus with the same identified influenza viral pneumonia J100: Influenza due to other identified influenza virus with pneumonia 2. Diagnosis of COVID-19 infection, defined by ICD-10 code: U07.1: COVID-19, virus identified 3. History of chronic obstructive pulmonary disease (COPD) (ICD-10 code: J44) 4. History of lung cancer or metastatic cancer involving the lungs 5. Current use of bronchodilators 6. Patients requiring oral suctioning only 7. Oxygen therapy with a flow rate \> 10 L/min 8. Clinical respiratory score \> 8 (Table 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Airway clearance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Airway clearance Pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.